CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

How Concentrated Should CJC-1295 & Ipamorelin Be for

Real Peptides Research TeamEditorial

Updated June 17, 202610 min read

57 WORDS

Short answer

A 2023 analysis published in the Journal of Pharmaceutical Sciences found that peptide stability degrades by up to 42% when reconstitution concentrations deviate more than 30% from manufacturer-validated ranges. Meaning the concentration you choose when mixing CJC-1295 no DAC and ipamorelin directly impacts experimental reproducibility before a single dose is administered. This isn't about preference or convenience.

Key takeaways

CJC-1295 no DAC should be reconstituted to 2mg/mL (5mg vial + 2.5mL bacteriostatic water) to balance peptide stability with accurate dosing in the 100–300mcg range.
Ipamorelin's smaller molecular weight permits concentrations up to 5mg/mL, but 2.5mg/mL (5mg vial + 2mL bacteriostatic water) improves measurement precision for doses below 300mcg.
Aggregation risk for CJC-1295 becomes detectable above 5mg/mL at physiological pH. Exceeding this threshold reduces bioavailability regardless of dose administered.
Reconstituted peptides stored at 2–8°C maintain stability for 28 days when prepared at validated concentrations; deviation above or below this range shortens the usable window.
Dose-per-draw calculation (target dose ÷ concentration) determines injection volume. Volumes below 0.05mL introduce measurement error that compounds across repeat administrations.

A 2023 analysis published in the Journal of Pharmaceutical Sciences found that peptide stability degrades by up to 42% when reconstitution concentrations deviate more than 30% from manufacturer-validated ranges. Meaning the concentration you choose when mixing CJC-1295 no DAC and ipamorelin directly impacts experimental reproducibility before a single dose is administered. This isn't about preference or convenience. It's about maintaining the molecular integrity that determines whether your research outcomes reflect the peptide's actual pharmacological activity or an artifact of improper preparation.

Our team works with research institutions across multiple countries, and we've seen firsthand how concentration errors cascade through entire study protocols. The gap between proper and improper reconstitution comes down to understanding three things most standard operating procedures never mention: the relationship between peptide mass and bacteriostatic water volume, the molar concentration thresholds that trigger aggregation, and the dose-per-draw calculation that prevents wastage or underdosing.

How concentrated should CJC-1295 no DAC and ipamorelin be for research purposes?

Standard research concentrations are 2mg/mL for CJC-1295 no DAC and 5mg/mL for ipamorelin when using bacteriostatic water as the diluent. These concentrations balance peptide stability (preventing aggregation at overly high concentrations) with practical dosing accuracy (avoiding dilutions so weak that target doses require impractically large injection volumes). Most experimental protocols use 5mg lyophilized vials reconstituted with 2.5mL bacteriostatic water for CJC-1295 and 2mL for ipamorelin. Yielding concentrations within validated stability ranges.

Here's what most researchers miss: the 'standard' concentration isn't universal. It's the validated midpoint for typical experimental dose ranges (100–300mcg CJC-1295, 200–500mcg ipamorelin per administration). If your protocol requires significantly higher or lower per-dose amounts, concentration must be adjusted proportionally. Not arbitrarily. This article covers exactly how peptide mass, diluent volume, and target dose interact to determine optimal concentration, what preparation mistakes negate stability entirely, and how to calculate precise reconstitution for non-standard experimental designs.

Why Peptide Concentration Matters Beyond the Dose

Concentration isn't just dilution math. It's a determinant of peptide quaternary structure stability. CJC-1295 no DAC (Mod GRF 1-29) and ipamorelin are both growth hormone secretagogues, but their stability profiles differ meaningfully. CJC-1295 contains 29 amino acids with a molecular weight of approximately 3,367 Da; ipamorelin is a pentapeptide at roughly 711 Da. The smaller molecular size of ipamorelin allows higher stable concentrations without aggregation risk, which is why validated ranges permit up to 10mg/mL for ipamorelin but cap CJC-1295 at 3–4mg/mL in most research settings.

Aggregation occurs when peptide molecules cluster into insoluble complexes. A process accelerated at concentrations above the peptide's critical micelle concentration (CMC). For CJC-1295, aggregation becomes detectable via turbidity measurements above approximately 5mg/mL at physiological pH. Once aggregated, the peptide loses bioavailability. It cannot bind to growth hormone secretagogue receptors (GHSR) effectively because the tertiary structure required for receptor binding is disrupted. This is why 'more concentrated is better' fails in peptide research: you're not creating a more potent solution, you're creating a less bioavailable one.

In our experience working with peptide suppliers across multiple experimental contexts, the reconstitution step is where most protocol deviations occur. Not from intent, but from misunderstanding the relationship between vial size, target dose, and administration frequency. Researchers accustomed to working with small molecules often apply dilution principles that don't translate to peptides, where hydrogen bonding, hydrophobic interactions, and pH sensitivity create constraints that simple molar calculations ignore.

Standard Concentration Calculations for CJC-1295 and Ipamorelin

The concentration you need depends on three variables: peptide mass per vial, intended dose per administration, and the volume your injection method can deliver accurately. Most research-grade syringes deliver 0.1mL (100 units on an insulin syringe) as the minimum practical volume for precise dosing. Volumes below this threshold introduce measurement error that compounds across repeat administrations.

For CJC-1295 no DAC, the standard approach uses a 5mg lyophilized vial reconstituted with 2.5mL bacteriostatic water, yielding 2mg/mL. At this concentration, a typical 200mcg dose requires 0.1mL (10 units on a 1mL insulin syringe). If your experimental protocol requires 300mcg per dose, the same 2mg/mL concentration demands 0.15mL. Still within the accurate dosing range for standard syringes. Reducing the bacteriostatic water to 2mL would yield 2.5mg/mL, allowing the same 300mcg dose in 0.12mL, but you're now operating closer to the aggregation threshold.

Ipamorelin follows similar logic with different numbers. A 5mg vial reconstituted with 1mL bacteriostatic water yields 5mg/mL. A 250mcg dose requires 0.05mL (5 units), which is at the lower edge of accurate insulin syringe measurement. Reconstituting the same 5mg vial with 2mL instead yields 2.5mg/mL, requiring 0.1mL for the same 250mcg dose. Doubling the injection volume but improving dosing precision meaningfully. The tradeoff: you've halved the number of doses per vial (from 20 doses at 5mg/mL to 10 doses at 2.5mg/mL assuming 250mcg per dose).

Calculation formula: Concentration (mg/mL) = Peptide mass (mg) ÷ Diluent volume (mL). Dose per draw (mL) = Target dose (mg) ÷ Concentration (mg/mL). Convert micrograms to milligrams by dividing by 1,000 (e.g., 200mcg = 0.2mg). This isn't optional algebra. It's the only way to prevent cumulative dosing error across multi-week experimental timelines.

CJC-1295 No DAC & Ipamorelin: Research Concentration Comparison

| Peptide | Standard Vial Size | Recommended Diluent Volume | Resulting Concentration | Dose Precision Range | Stability Duration (2–8°C) | Professional Assessment | |---|---|---|---|---|---| | CJC-1295 no DAC | 5mg lyophilized | 2.5mL bacteriostatic water | 2mg/mL | 100–300mcg per 0.05–0.15mL | 28 days post-reconstitution | Optimal balance between stability and dosing accuracy for typical GH secretagogue research protocols. Aggregation risk minimal at this concentration | | Ipamorelin | 5mg lyophilized | 2mL bacteriostatic water | 2.5mg/mL | 200–500mcg per 0.08–0.2mL | 28 days post-reconstitution | Preferred for protocols requiring precise low-dose titration. Higher concentrations (5mg/mL) increase vial efficiency but reduce measurement accuracy below 0.1mL | | CJC-1295 + Ipamorelin (combined vial) | 5mg CJC + 5mg IPA | 3mL bacteriostatic water | 1.67mg/mL CJC, 1.67mg/mL IPA | Typical ratio 1:2 or 1:3 CJC:IPA by dose | 21 days post-reconstitution | Co-administration simplifies dosing schedules but shortens stability window. Peptide interaction in solution accelerates degradation compared to separate vials |

What If: CJC-1295 & Ipamorelin Research Scenarios

What If Your Experimental Protocol Requires Doses Outside the Standard Range?

Recalculate concentration to keep injection volumes between 0.05–0.3mL per administration. For a 500mcg ipamorelin dose, a 5mg/mL concentration requires 0.1mL. Within range. But for a 100mcg dose at the same concentration, you'd need 0.02mL, which is below reliable syringe accuracy. Solution: dilute to 2mg/mL instead, requiring 0.05mL for the same 100mcg dose. The principle: adjust concentration to match your dose, not the other way around.

What If You're Using Pre-Mixed CJC-1295 and Ipamorelin in a Single Vial?

Combined formulations typically contain equal masses of each peptide (e.g., 5mg CJC + 5mg ipamorelin in one vial). Reconstitute with 3–4mL bacteriostatic water to achieve approximately 1.25–1.67mg/mL for each peptide. Co-administration shortens stability. Use within 21 days instead of the standard 28-day window for single-peptide vials. The interaction between the two peptides in solution accelerates oxidative degradation, particularly for CJC-1295's methionine residues.

What If the Reconstituted Solution Appears Cloudy or Contains Visible Particles?

Discard it. Cloudiness indicates aggregation or contamination. Neither is reversible. Aggregated peptides lose tertiary structure required for GHSR binding, rendering the solution pharmacologically inactive regardless of concentration. Contamination introduces microbial or particulate matter that invalidates experimental sterility. This typically results from improper storage (temperature excursion above 8°C), expired bacteriostatic water (benzyl alcohol degrades over time), or shaking the vial during reconstitution instead of gently swirling.

What If You Need to Store Unreconstituted Peptide Long-Term?

Lyophilized CJC-1295 and ipamorelin stored at −20°C remain stable for 24–36 months from manufacture date. Once reconstituted, refrigerate at 2–8°C and use within 28 days. Freezing reconstituted peptides is not recommended. Ice crystal formation during the freeze-thaw cycle disrupts peptide structure irreversibly. For extended experimental timelines, reconstitute only the number of vials needed for a 4-week period rather than preparing the entire stock upfront.

The Blunt Truth About Research Peptide Concentration

Here's the honest answer: most concentration errors in peptide research aren't from lack of knowledge. They're from applying principles from small-molecule pharmacology that don't translate. Peptides aren't just smaller proteins; they're structurally fragile compounds where concentration, pH, temperature, and storage duration interact in ways that molar calculations alone don't predict. The 'standard' concentrations cited in most research guidelines (2mg/mL for CJC-1295, 5mg/mL for ipamorelin) aren't arbitrary. They represent the empirically validated midpoint where aggregation risk, dosing accuracy, and stability duration converge for typical experimental dose ranges.

Deviate from these ranges without recalculating for your specific protocol variables, and you're not customizing your approach. You're introducing uncontrolled variables that make cross-study comparisons meaningless. A study using 6mg/mL CJC-1295 isn't testing the same compound as one using 2mg/mL, even if the administered dose is identical, because aggregation at higher concentrations alters the bioavailable fraction unpredictably.

Reconstitution Best Practices for Experimental Reproducibility

Bacteriostatic water is the standard diluent for peptide reconstitution because the 0.9% benzyl alcohol preservative inhibits bacterial growth for 28 days post-mixing. Sterile water lacks this preservative. Use it only for same-day administration. The reconstitution process itself matters as much as the final concentration: inject bacteriostatic water slowly down the inside wall of the vial, not directly onto the lyophilized peptide cake, to prevent foaming. Swirl gently. Never shake. Shaking introduces air bubbles that denature peptides at the liquid-air interface.

Temperature control begins before reconstitution. Lyophilized vials should reach room temperature (20–25°C) before adding bacteriostatic water. Injecting cold diluent into a refrigerated vial creates condensation that dilutes the final concentration unpredictably. Once reconstituted, return the vial to 2–8°C refrigeration immediately. Every hour at room temperature accelerates degradation. CJC-1295 loses approximately 3–5% potency per 24 hours at 25°C, compounding over multi-week storage.

Draw technique affects concentration consistency across doses. Insert the needle, invert the vial, and withdraw slowly to avoid introducing air into the solution. Air bubbles displace liquid volume. A 0.1mL draw containing 0.02mL air delivers only 0.08mL of actual peptide solution, creating a 20% underdose. For multi-dose vials, this error compounds: the first five draws may be accurate, but by draw ten, cumulative air displacement has altered the remaining concentration meaningfully.

Our team's recommendation for researchers new to peptide work: prepare a detailed reconstitution log that records peptide lot number, reconstitution date, diluent volume, calculated concentration, and the date of each dose drawn. This documentation allows you to correlate any unexpected experimental outcomes with preparation variables. A step that becomes critical when troubleshooting inconsistent results across cohorts or timepoints.

When you're working with compounds that require this level of preparation precision, sourcing matters as much as technique. Our dedication to quality extends across our entire product line. From research-grade peptides synthesized under controlled conditions to specialized formulations like the FAT Loss Stack. Every batch undergoes third-party verification to confirm amino acid sequencing accuracy and purity before release.

The concentration you choose for CJC-1295 and ipamorelin isn't a minor detail. It's a foundational variable that determines whether your experimental outcomes reflect true peptide pharmacology or preparation artifacts. Standard concentrations exist because they've been validated across thousands of research protocols, not because they're convenient. When your study design requires deviation from these standards, the underlying calculation principles remain the same: match concentration to dose, keep injection volumes within accurate measurement range, and prioritize peptide stability over vial efficiency. Get the reconstitution right, and every dose that follows is built on a foundation of reproducible precision.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

The standard research concentration for CJC-1295 no DAC is 2mg/mL, achieved by reconstituting a 5mg lyophilized vial with 2.5mL bacteriostatic water. This concentration balances peptide stability (preventing aggregation) with dosing accuracy for typical experimental dose ranges of 100–300mcg per administration. Higher concentrations (above 4–5mg/mL) increase aggregation risk, while lower concentrations require impractically large injection volumes that reduce measurement precision.

Yes, CJC-1295 and ipamorelin can be combined in a single vial, typically at equal masses (e.g., 5mg of each peptide). Reconstitute combined formulations with 3–4mL bacteriostatic water to achieve approximately 1.25–1.67mg/mL for each peptide. However, co-mixing shortens stability duration to approximately 21 days (versus 28 days for separate vials) because peptide interaction in solution accelerates oxidative degradation, particularly affecting CJC-1295's methionine residues.

Reconstituted CJC-1295 and ipamorelin stored at 2–8°C in bacteriostatic water remain stable for 28 days post-reconstitution when prepared at validated concentrations (2mg/mL for CJC-1295, 2.5–5mg/mL for ipamorelin). Stability degrades significantly outside this temperature range — approximately 3–5% potency loss per 24 hours at room temperature (25°C). Unreconstituted lyophilized peptides stored at −20°C maintain stability for 24–36 months from manufacture date.

For ipamorelin doses below 200mcg per administration, use a 2.5mg/mL concentration rather than the higher 5mg/mL standard. This is achieved by reconstituting a 5mg vial with 2mL bacteriostatic water instead of 1mL. The lower concentration allows dose volumes above 0.05mL, which is the minimum practical volume for accurate measurement with standard insulin syringes — doses requiring smaller volumes introduce measurement error that compounds across repeat administrations.

Cloudiness or visible particles indicate peptide aggregation or contamination, both of which render the solution unusable. Aggregation occurs when peptides cluster into insoluble complexes, typically from exceeding the critical aggregation concentration (above ~5mg/mL for CJC-1295), improper reconstitution technique (shaking instead of swirling), or temperature excursions above 8°C during storage. Contamination results from expired bacteriostatic water or non-sterile preparation. Discard any cloudy solution — aggregated peptides lose bioavailability irreversibly.

Use this formula: Injection volume (mL) = Target dose (mg) ÷ Concentration (mg/mL). Convert micrograms to milligrams by dividing by 1,000 (e.g., 250mcg = 0.25mg). Example: for a 200mcg (0.2mg) dose of CJC-1295 at 2mg/mL concentration, injection volume = 0.2 ÷ 2 = 0.1mL (10 units on a 1mL insulin syringe). Volumes below 0.05mL are difficult to measure accurately and should prompt concentration adjustment rather than smaller draw volumes.

Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, inhibiting bacterial growth for 28 days post-reconstitution — this is the standard diluent for multi-dose peptide vials used over several weeks. Sterile water lacks this preservative and should only be used for same-day administration, as it cannot prevent microbial contamination during storage. Using sterile water for multi-dose vials introduces infection risk and invalidates experimental sterility protocols.

No, freezing reconstituted peptides is not recommended. Ice crystal formation during the freeze-thaw cycle disrupts peptide tertiary and quaternary structure irreversibly, reducing bioavailability unpredictably. While lyophilized (unreconstituted) peptides remain stable at −20°C for 24–36 months, once reconstituted they should be refrigerated at 2–8°C and used within 28 days. For extended experimental timelines, reconstitute only the number of vials needed for a 4-week period rather than preparing the entire stock upfront.

The three most common errors are: (1) Shaking the vial instead of gently swirling, which introduces air bubbles that denature peptides at the liquid-air interface. (2) Injecting bacteriostatic water directly onto the lyophilized peptide cake rather than down the vial wall, causing foaming and structural damage. (3) Reconstituting a refrigerated vial without allowing it to reach room temperature first, creating condensation that dilutes the final concentration unpredictably. Each of these errors reduces peptide potency before the first dose is administered.

Aggregation causes peptides to form insoluble clusters that lose the tertiary structure required for receptor binding — meaning aggregated CJC-1295 cannot effectively bind to growth hormone secretagogue receptors (GHSR) even if the total peptide mass in the dose is correct. This creates a discrepancy between administered dose and bioavailable dose, making cross-study comparisons meaningless. A study using 6mg/mL CJC-1295 (high aggregation risk) is not testing the same effective compound as one using 2mg/mL, even if both administer 200mcg per dose.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA